Oncolytic viruses: From bench to bedside with a focus on safety
2015; Taylor & Francis; Volume: 11; Issue: 7 Linguagem: Inglês
10.1080/21645515.2015.1037058
ISSN2164-554X
AutoresPascal Buijs, Judith HE Verhagen, Casper HJ van Eijck, Bernadette G. van den Hoogen,
Tópico(s)CAR-T cell therapy research
ResumoOncolytic viruses are a relatively new class of anti-cancer immunotherapy agents. Several viruses have undergone evaluation in clinical trials in the last decades, and the first agent is about to be approved to be used as a novel cancer therapy modality. In the current review, an overview is presented on recent (pre)clinical developments in the field of oncolytic viruses that have previously been or currently are being evaluated in clinical trials. Special attention is given to possible safety issues like toxicity, environmental shedding, mutation and reversion to wildtype virus.
Referência(s)